Affilogic is a private biotech company specialized in discovering and developing Nanofitins^®-based therapeutics, through in house programs or collaborations with worldwide industry leaders in the pharmaceutical sector.

Recent news :

Nov 2024 – Affilogic is presenting at the next I4ID congress : Perring Jacquot is presenting latest data on anti-influenza Nanofitin^®-based therapeutics. Pulmonary delivered anti-influenza Nanofitins^® exert very promising efficacy results in-vivo in mice.

Nov 2024 – Affilogic CSO Mathieu Cinier is presenting at PEGS Europe 2025: Mathieu will present new approaches using Nanofitins^® to treat infectious disease. Nanofitin^® alternative scaffold generation platform allows for the generation of therapeutic candidates of high neutralisation potential in roughly 100 days, and can be amenable to local treatment in the case of pulmonary diseases.